Delving into the Latest Updates on Sunol Molecular Corp. with Synapse

Overview

Basic Info

Introduction

Sunol Molecular Corp., a division of ImmunityBio, Inc., is a US-based company headquartered in Miramar, FL. The company specializes in creating gel therapeutics for the treatment of human tissue factor-related disorders. Founded by Peter R. Rhode, Hing C. Wong, and Jon Weidanz, Sunol Molecular Corp. was acquired by Altor BioScience Corp., a subsidiary of ImmunityBio, Inc. as of March 25, 2005.

Tags

Immune System Diseases

Digestive System Disorders

Respiratory Diseases

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Monoclonal antibody	1

Top 5 Target	Count

tissue factor	1

SummaryTissue factor (TF) antagonists targeting the factor VII (FVII) binding domain have been shown to interrupt acute vascular thrombus formation without impairing haemostasis in non-human primates. In this study, we evaluate whether a human/mouse chimeric monoclonal antibody (ALT-836, formerly known as Sunol-cH36) blocking the factor X/factor IX (FX/FIX) binding site of tissue factor could achieve similar clinical benefits in an arterial thrombosis model induced by surgical endarterectomy in chimpanzees. In this model, sequential surgical endarterectomies on right and left superficial femoral arteries were performed 30 days apart in five chimpanzees. A bolus (1 mg/kg) of ALT-836 was injected intravenously immediately preceding the restoration of flow in the endarterectomised femoral artery. Pre-surgical labelling of autologous platelets using 111In-Oxine and post-surgical gamma camera imaging of 111In-platelet deposition at endarterectomy sites was performed. The manipulated arterial segments were harvested for patency analysis 30 days following surgery. The results indicate that ALT-836 was highly effective at reducing acute vascular thrombosis, with no significant variations in surgical blood loss and template-bleeding time in the treated group compared to the control animals. These data suggest that ALT-836 is an effective and safe antithrombotic agent in preventing TF-initiated vascular thrombogenesis without compromising haemostasis.

01 Jan 2006·American Journal of Physiology-Lung Cellular and Molecular PhysiologyQ2 · MEDICINE

Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure

Q2 · MEDICINE

Article

Author: Andrew J. Ghio ; Karen E. Welty-Wolf ; Jin An Jiao ; Martha S. Carraway ; Claude A. Piantadosi ; Jack Egan ; Xiaoyun Zhu ; Thomas L. Ortel ; Hing C. Wong ; Steven Idell

Tissue factor expression in sepsis activates coagulation in the lung, which potentiates inflammation and leads to fibrin deposition. We hypothesized that blockade of factor X binding to the tissue factor-factor VIIa complex would prevent sepsis-induced damage to the lungs and other organs. Acute lung injury was produced in 15 adult baboons primed with killed Escherichia coli [1 × 109colony-forming units (CFU)/kg], and then 12 h later, they were given 1 × 1010CFU/kg live E. coli by infusion. Two hours after live E. coli, animals received antibiotics with or without monoclonal antibody to tissue factor intravenously to block tissue factor-factor X binding. The animals were monitored physiologically for 34 h before being killed and their tissue harvested. The antibody treatment attenuated abnormalities in gas exchange and lung compliance, preserved renal function, and prevented tissue neutrophil influx and bowel edema relative to antibiotics alone (all P < 0.05). It also attenuated fibrinogen depletion ( P < 0.01) and decreased proinflammatory cytokines, e.g., IL-6 and -8 ( P < 0.01), in systemic and alveolar compartments. Similar protective effects of the antibody on IL-6 and -8 expression and permeability were found in lipopolysaccharide-stimulated endothelial cells. Blockade of factor X binding to the tissue factor-factor VIIa complex attenuates lung and organ injuries in established E. coli sepsis by attenuating the neutrophilic response and inflammatory pathways.

01 May 2005·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

Phase 1 Safety and Pharmacokinetic Study of Chimeric Murine-Human Monoclonal Antibody cαStx2 Administered Intravenously to Healthy Adult Volunteers

Q2 · MEDICINE

Article

Author: Melton-Celsa, Angela ; Chavaillaz, Pierre A. ; Thuning-Roberson, Claire ; Young, David G. ; Edelman, Robert ; Tacket, Carol O. ; Dowling, Thomas C. ; O'Brien, Alison

ABSTRACT Hemolytic-uremic syndrome (HUS) is a serious complication of infection by Shiga toxin-producing Escherichia coli . Shiga toxin type 2 (Stx2) is responsible for the renal toxicity that can follow intestinal infection and hemorrhagic colitis due to E. coli . A chimeric mouse-human antibody, designated cαStx2, that has neutralizing activity in a mouse model was produced and tested in healthy adult volunteers. In this phase I dose escalation study, cαStx2 was generally well tolerated. Pharmacokinetic studies indicated that clearance was stable over the dose range of 1.0 to 10 mg/kg of body weight (0.249 ± 0.023 ml/kg/h) but was higher for the 0.1-mg/kg dose (0.540 ± 0.078 ml/kg/h), suggesting saturable elimination. A similar nonlinear trend was observed for the volume of distribution, where average values ranged from 0.064 ± 0.015 liter/kg for the 1.0- to 10-mg/kg doses and 0.043 ± 0.005 for the 0.01-mg/kg dose. The relatively small volume of distribution suggests that the antibody is limited to the vascular (plasma) compartment. The mean half-life was 165 ± 66 h, with lowest values observed for the 0.1-mg/kg dose (56.2 ± 9.7 h) and the highest values reported for the 10.0-mg/kg dose (206.4 ± 12.4 h). Future studies are needed to confirm the safety of this cαStx2, and innovative clinical trials will be required to measure its efficacy in preventing or treating HUS.

100 Deals associated with Sunol Molecular Corp.

Login to view more data

100 Translational Medicine associated with Sunol Molecular Corp.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ALT-836 ( tissue factor )	Respiratory Distress Syndrome, Adult More	Phase 2
Single chain T cell receptors (Sunol Molecular)	Neoplasms More	Discontinued
Anti-Shiga toxin monoclonal antibodies(Sunol Molecular Corp.) ( Shiga toxin )	Escherichia Coli Infections More	Discontinued